Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

May 5, 2023

Study Completion Date

May 31, 2023

Conditions
DysphagiaCerebral Small Vessel DiseasesCognitive Impairment
Interventions
DRUG

Stellate ganglion block

Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

BEHAVIORAL

Rehabilitation therapy

"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."

Trial Locations (1)

Unknown

Zhen Da No.1 Fushu Hos., Huabei

All Listed Sponsors
lead

Zeng Changhao

OTHER

NCT06176404 - Stellate Ganglion Block in Patients With Cerebral Small Vessel Disease | Biotech Hunter | Biotech Hunter